Empirical Asset Management, LLC Biogen Inc. Transaction History

Empirical Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$190.52 - $236.72 $28,578 - $35,508	-150 Reduced 14.63%	875 $202,000
Q1 2024 May 10, 2024	SELL	$212.02 - $267.71 $61,485 - $77,635	-290 Reduced 22.05%	1,025 $221,000
Q4 2023 Jan 12, 2024	BUY	$222.59 - $267.94 $23,594 - $28,401	106 Added 8.77%	1,315 $340,000
Q2 2023 Aug 01, 2023	SELL	$275.25 - $318.06 $27,525 - $31,806	-100 Reduced 7.64%	1,209 $344,000
Q1 2023 Apr 18, 2023	SELL	$256.56 - $292.34 $395,615 - $450,788	-1,542 Reduced 54.09%	1,309 $363,000
Q4 2022 Jan 31, 2023	SELL	$252.44 - $306.72 $84,314 - $102,444	-334 Reduced 10.49%	2,851 $789,000
Q3 2022 Oct 19, 2022	BUY	$194.69 - $268.46 $620,087 - $855,045	3,185 New	3,185 $850,000
Q2 2022 Jul 18, 2022	SELL	$187.54 - $223.02 $596,939 - $709,872	-3,183 Closed	0 $0
Q1 2022 May 06, 2022	BUY	$193.77 - $244.14 $389,865 - $491,209	2,012 Added 171.82%	3,183 $670,000
Q4 2021 May 06, 2022	BUY	$223.92 - $287.77 $262,210 - $336,978	1,171 New	1,171 $281,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Empirical Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Empirical Asset Management, LLC with notifications on news.